Geoffrey Herkes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4546125/publications.pdf

Version: 2024-02-01

361413 315739 1,466 48 20 38 citations h-index g-index papers 48 48 48 2118 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Enhancing quality of life among epilepsy surgery patients: Interlinking multiple social and relational determinants. Epilepsy and Behavior, 2020, 102, 106721.	1.7	10
2	Identification and referral of patients with refractory epilepsy from the primary to the tertiary care interface in New South Wales, Australia. Epilepsy and Behavior, 2020, 111, 107232.	1.7	9
3	Hospital service utilization trajectories of individuals living with epilepsy in New South Wales, Australia, 2012–2016: A population-based study. Epilepsy and Behavior, 2020, 105, 106941.	1.7	6
4	Heidenhain variant sporadic Creutzfeldt-Jakob disease diagnosed as an autoimmune encephalitis due to a false-positive GAD autoantibody. BMJ Case Reports, 2019, 12, e229018.	0.5	4
5	Promoting faster pathways to surgery: a clinical audit of patients with refractory epilepsy. BMC Neurology, 2019, 19, 29.	1.8	15
6	Impact of chronic health conditions and injury on school performance and health outcomes in New South Wales, Australia: a retrospective record linkage study protocol. BMJ Paediatrics Open, 2019, 3, e000530.	1.4	11
7	Determinants of health and wellbeing in refractory epilepsy and surgery: The Patient Reported, ImpleMentation sciEnce (PRIME) model. Epilepsy and Behavior, 2019, 92, 79-89.	1.7	8
8	Republished: Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab. Drug and Therapeutics Bulletin, 2019, 57, 141-143.	0.3	1
9	Leading up to saying "yes": A qualitative study on the experience of patients with refractory epilepsy regarding presurgical investigation for resective surgery. Epilepsy and Behavior, 2018, 83, 36-43.	1.7	14
10	Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. Journal of the Neurological Sciences, 2018, 387, 115-118.	0.6	72
11	Examining health service utilization, hospital treatment cost, and mortality of individuals with epilepsy and status epilepticus in New South Wales, Australia 2012–2016. Epilepsy and Behavior, 2018, 79, 9-16.	1.7	30
12	Reversible cerebral vasoconstriction syndrome. Neuropsychological Rehabilitation, 2018, 28, 223-233.	1.6	3
13	Better evidence for earlier assessment and surgical intervention for refractory epilepsy (The BEST) Tj ETQq1 1 0.7	/84314 rgl 1.9	BT/Overlock
14	Immune mediated neuropathy following checkpoint immunotherapy. Journal of Clinical Neuroscience, 2017, 45, 14-17.	1.5	49
15	Riskâ€adjusted hospital mortality rates for stroke: evidence from the Australian Stroke Clinical Registry (AuSCR). Medical Journal of Australia, 2017, 206, 345-350.	1.7	37
16	Orphan drugs in Australia. Expert Opinion on Orphan Drugs, 2016, 4, 1195-1197.	0.8	4
17	Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study. BMJ Open, 2016, 6, e008203.	1.9	10
18	Rapid access point of care clinic for transient ischemic attacks and minor strokes. Journal of Clinical Neuroscience, 2016, 23, 106-110.	1.5	11

#	Article	IF	CITATIONS
19	Neutrophil to lymphocyte ratio and early clinical outcome in patients with acute ischemic stroke. Journal of the Neurological Sciences, 2015, 357, e102.	0.6	0
20	Use of infliximab and other biologics in <scp>B</scp> ehçet disease. Internal Medicine Journal, 2014, 44, 96-100.	0.8	3
21	Sickle cell disease and posterior reversible leukoencephalopathy. Journal of Clinical Neuroscience, 2014, 21, 1329-1332.	1.5	15
22	Angiostrongylus meningoencephalitis: survival from minimally conscious state to rehabilitation. Medical Journal of Australia, 2013, 198, 440-442.	1.7	22
23	De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nature Genetics, 2012, 44, 1030-1034.	21.4	345
24	The neurologic manifestations of the acute porphyrias. Journal of Clinical Neuroscience, 2011, 18, 1147-1153.	1.5	64
25	Parkinsonism–hyperpyrexia syndrome: The role of electroconvulsive therapy. Journal of Clinical Neuroscience, 2006, 13, 857-859.	1.5	24
26	Patient Recognition of and Response to Symptoms of TIA or Stroke. Neuroepidemiology, 2006, 26, 168-175.	2.3	83
27	Results of a Multicentre, Randomised Controlled Trial of Intra-Arterial Urokinase in the Treatment of Acute Posterior Circulation Ischaemic Stroke. Cerebrovascular Diseases, 2005, 20, 12-17.	1.7	185
28	Stereochemistry in clinical medicine: a neurological perspective. Journal of Clinical Neuroscience, 2003, 10, 649-654.	1.5	31
29	Fatal brain stem event complicating acute pancreatitis. Journal of Clinical Neuroscience, 2003, 10, 351-358.	1.5	6
30	Barbiturates for acute neurological and neurosurgical emergencies – do they still have a role?. Journal of Clinical Neuroscience, 2003, 10, 283-288.	1.5	20
31	Prolonged Thiopentone Infusion for Neurosurgical Emergencies: Usefulness of Therapeutic Drug Monitoring. Anaesthesia and Intensive Care, 2001, 29, 339-348.	0.7	21
32	7: Epilepsy. Medical Journal of Australia, 2001, 174, 534-539.	1.7	1
33	Postoperative seizure outcome in a series of 114 patients with supratentorial arteriovenous malformations. Journal of Clinical Neuroscience, 2000, 7, 107-111.	1.5	55
34	Stereoselective interaction of thiopentone enantiomers with the GABAA receptor. British Journal of Pharmacology, 1999, 128, 77-82.	5.4	33
35	Transient visual obscurations and headache in aqueduct stenosis exacerbated by menstruation. Journal of Clinical Neuroscience, 1998, 5, 245-246.	1.5	0
36	Is Sydenham's chorea an antiphospholipid syndrome?. Journal of Clinical Neuroscience, 1998, 5, 115-118.	1.5	27

3

#	Article	IF	CITATIONS
37	Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone. British Journal of Clinical Pharmacology, 1997, 43, 355-362.	2.4	19
38	An unusual sideâ€effect of longâ€ŧerm methysergide treatment. Australian and New Zealand Journal of Medicine, 1995, 25, 171-171.	0.5	3
39	Drug Treatment of Catamenial Epilepsy. CNS Drugs, 1995, 3, 260-266.	5.9	2
40	Patterns of seizure occurence in catamenial epilepsy. Epilepsy Research, 1993, 15, 47-52.	1.6	43
41	Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal British Journal of Clinical Pharmacology, 1993, 35, 609-613.	2.4	11
42	Effects of Midazolam on Electroencephalograms of Seriously Ill Patients. Mayo Clinic Proceedings, 1992, 67, 334-338.	3.0	23
43	Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin British Journal of Clinical Pharmacology, 1991, 31, 171-174.	2.4	44
44	Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy. Epilepsy Research, 1990, 6, 146-154.	1.6	41
45	Magnetic resonance imaging in clinicallyâ€definite multiple sclerosis. Medical Journal of Australia, 1990, 152, 136-140.	1.7	9
46	Simultaneous quantitation of salivary carbamazepine, carbamazepine-10,11-epoxide, phenytoin and phenobarbitone by high-performance liquid chromatography. Biomedical Applications, 1989, 496, 147-154.	1.7	13
47	CEREBRAL NOCARDIOSIS – CLINICAL AND PATHOLOGICAL FINDINGS IN THREE PATIENTS. Australian and New Zealand Journal of Medicine, 1989, 19, 475-478.	0.5	17
48	Hospital service use for young people with chronic health conditions: A populationâ€based matched retrospective cohort study. Journal of Paediatrics and Child Health, 0, , .	0.8	0